{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-067511","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.385604+00:00","generated_at":"2026-05-22T01:51:06.309387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma Q1 net loss $17.5M; Phase 2 interim data expected mid-2025","bullets":["Phase 2 PYNNACLE interim analysis mid-2025; data for ~50 patients with ≥18 weeks follow-up.","Cash $165.8M as of March 31, 2025 vs $183.3M Dec 31, 2024; runway to end of 2026.","Net loss Q1 2025 $17.5M ($15.3M Q1 2024); R&D expenses $17.4M vs $13.2M.","G&A expenses decreased to $4.1M from $5.0M on reduced headcount and facility spend.","Rezatapopt discovery paper published in Cancer Discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-067511","json":"https://secwatch.observer/filing/0000950170-25-067511.json","markdown":"https://secwatch.observer/filing/0000950170-25-067511.md","text":"https://secwatch.observer/filing/0000950170-25-067511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/0000950170-25-067511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/pmvp-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:51:06.309387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}